Acute kidney injury (AKI) is a sudden, often reversible decline in kidney function — defined as a rise in serum creatinine of 26 µmol/L or more within 48 hours, a 50% or greater rise within 7 days, or urine output below 0.5 ml/kg/hour for more than 6 hours. AKI is caused by reduced blood flow to the kidneys (pre-renal — from dehydration, heart failure, or sepsis), direct damage to kidney cells (intrinsic — from infection, toxins, or glomerulonephritis), or obstruction of urinary flow (post-renal — from stones, BPH, or tumour). It is one of the most common hospital complications, affecting 5 to 20% of hospitalised patients.

Early identification and treatment of the underlying cause is the most important intervention — restoring renal perfusion in pre-renal AKI, removing the nephrotoxin in intrinsic AKI, or relieving the obstruction in post-renal AKI. CRRT (continuous renal replacement therapy) supports patients through severe AKI at KIMS while the kidneys recover. Most AKI recovers completely — but repeated episodes or prolonged severe AKI cause permanent CKD.

An adrenal incidentaloma is an adrenal mass discovered unexpectedly on imaging performed for another reason — typically abdominal CT or MRI. Found in approximately 4 to 5% of all CT scans, the majority are benign, non-functioning cortical adenomas requiring no treatment. However, every adrenal incidentaloma must be assessed for two critical questions: Is it hormonally active (producing excess cortisol, aldosterone, or adrenaline)? And is it malignant (adrenocortical carcinoma or metastasis)?

Hormonal testing — 1mg overnight dexamethasone suppression test, plasma metanephrines, and aldosterone-to-renin ratio — screens all three hormonal syndromes. CT characteristics (Hounsfield units, size, and contrast washout) assess malignancy risk. Masses above 4 cm, with poor washout or irregular margins, or with confirmed hormonal activity undergo robotic adrenalectomy at KIMS. All others are surveyed annually.

Adrenal insufficiency is the failure of the adrenal glands to produce adequate cortisol — from destruction of the adrenal cortex (primary, Addison's disease) or failure of ACTH stimulation from the pituitary or hypothalamus (secondary). It causes fatigue, weight loss, nausea, postural hypotension, and — in acute adrenal crisis — life-threatening shock with severe hyponatraemia and hyperkalaemia. In India, the most common cause of primary adrenal insufficiency is tuberculosis destroying the adrenal cortex.

Adrenal crisis (acute adrenal insufficiency) is an emergency — immediate IV hydrocortisone 100mg is life-saving and must be given before blood test results are available. Diagnosis after the crisis: morning cortisol and ACTH stimulation test. Treatment: lifelong hydrocortisone replacement plus fludrocortisone for primary AI. Every patient carries a steroid emergency card and knows to double or triple their dose during illness, surgery, or significant physical stress.

Albuminuria is the presence of albumin in the urine — a marker of glomerular damage (the filtration barrier normally prevents albumin from passing into the urine). It is classified as: microalbuminuria (now called 'moderately increased albuminuria' — albumin-to-creatinine ratio ACR 3 to 30 mg/mmol), the earliest sign of diabetic nephropathy and a predictor of cardiovascular disease; and macroalbuminuria or proteinuria (ACR above 30 mg/mmol), indicating more advanced glomerular disease.

Albuminuria is not a diagnosis but a marker of kidney damage that determines urgency of evaluation and treatment. ACE inhibitors and ARBs reduce albuminuria and slow CKD progression independently of blood pressure. SGLT2 inhibitors reduce albuminuria in diabetic and non-diabetic CKD. At KIMS, urine ACR is checked at every nephrology visit and annually in all patients with diabetes or hypertension.

Alport syndrome is a hereditary kidney disease caused by mutations in the genes encoding type IV collagen (COL4A3, COL4A4, or COL4A5) — the structural protein of the glomerular basement membrane (GBM). The defective GBM tears under the mechanical stress of filtration, causing progressive haematuria, proteinuria, and CKD that progresses to ESRD — typically by age 20 to 30 in X-linked males. Associated with high-frequency sensorineural hearing loss and ocular abnormalities (anterior lenticonus). Kidney biopsy with electron microscopy shows the characteristic GBM thinning, splitting, and layering — the 'basket-weave' pattern on EM.

ACE inhibitor therapy slows progression significantly — recommended at the microhaematuria stage before proteinuria appears. Genetic testing identifies the causative mutation and guides prognosis (COL4A5 mutation in X-linked males has the worst prognosis). Kidney transplant is the treatment for ESRD — the transplanted kidney has normal type IV collagen. At KIMS, genetic counselling and family cascade screening are offered to all Alport families.

Renal amyloidosis is the deposition of misfolded protein fibrils (amyloid) in the kidney — causing progressive proteinuria, nephrotic syndrome, and CKD. The two most common types affecting the kidney: AL amyloidosis (from plasma cell dyscrasia — the same mechanism as multiple myeloma, where misfolded light chains form amyloid fibrils) and AA amyloidosis (from chronic inflammation — rheumatoid arthritis, inflammatory bowel disease, chronic infections, tuberculosis — where serum amyloid A protein is the fibril precursor). Diagnosis requires kidney biopsy showing Congo red positive staining with apple-green birefringence under polarised light.

AL amyloidosis is treated with bortezomib-based or daratumumab-based chemotherapy targeting the plasma cell clone. AA amyloidosis is treated by controlling the underlying inflammatory disease. Prognosis depends on the extent of systemic involvement — cardiac amyloidosis (which causes restrictive cardiomyopathy) determines prognosis more than the kidney involvement. At KIMS, AL and AA amyloidosis are managed with the haematology-oncology team.

ANCA-associated vasculitis (ANCA-AAV) is a group of small vessel vasculitides characterised by positive antineutrophil cytoplasmic antibodies (MPO-ANCA or PR3-ANCA) and pauci-immune glomerulonephritis on kidney biopsy. The three subtypes: granulomatosis with polyangiitis (GPA — previously Wegener's), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA — previously Churg-Strauss). The kidney presents with rapidly progressive glomerulonephritis — haematuria, red cell casts, rising creatinine — that can progress to dialysis within days without treatment.

Emergency treatment with high-dose prednisolone and rituximab (or cyclophosphamide in severe cases) is required for active ANCA glomerulonephritis. Plasma exchange may be added for severe disease with dialysis requirement. CRRT supports AKI while immunosuppression takes effect. At KIMS, ANCA vasculitis is a nephrology emergency with 24/7 availability.

Antiphospholipid syndrome is an autoimmune hypercoagulable disorder characterised by antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, anti-beta-2-glycoprotein I) causing arterial and venous thrombosis and pregnancy morbidity (recurrent miscarriage, foetal loss). The kidney is affected by APS nephropathy — small vessel thrombosis causing ischaemic injury, renovascular hypertension, and progressive CKD. Renal vein thrombosis and renal artery stenosis also occur.

Long-term anticoagulation with warfarin (INR 2–3) is the cornerstone of treatment for confirmed APS with thrombotic events. DOACs are not recommended as first-line for arterial thrombosis or triple antibody positivity. Pregnancy management with LMWH and aspirin significantly reduces obstetric losses. At KIMS, APS is managed in the women's nephrology programme.

Bartter syndrome is a rare hereditary renal tubular disorder characterised by hypokalaemia, metabolic alkalosis, and normal or low blood pressure despite markedly elevated renin and aldosterone. It is caused by mutations in ion transport proteins in the thick ascending limb of the loop of Henle — impairing sodium, potassium, and chloride reabsorption. The kidneys waste these electrolytes and produce prostaglandins in excess, causing polyuria and polydipsia from childhood, growth retardation, muscle weakness from hypokalaemia, and medullary nephrocalcinosis.

Bartter syndrome is distinguished from Gitelman syndrome (which involves the distal tubule) by its earlier onset, more severe presentation, and the association with nephrocalcinosis. Treatment: potassium supplementation, potassium-sparing diuretics (spironolactone, amiloride), and NSAIDs (which block prostaglandin synthesis and reduce urinary salt wasting — one of the few conditions where NSAIDs are beneficial rather than harmful to the kidney). At KIMS, rare tubular disorders are evaluated through the metabolic nephrology programme.

Benign prostatic hyperplasia (BPH) is the non-malignant enlargement of the prostate gland — the most common urological condition in men above 50, affecting over 50% of men by age 60 and over 80% by age 80 in India. The enlarged prostate obstructs the bladder outlet, causing lower urinary tract symptoms (LUTS): reduced urinary flow, hesitancy, straining, incomplete emptying, frequency, urgency, and nocturia. Prolonged untreated BPH causes bladder dysfunction (trabeculation, diverticula, detrusor failure), recurrent UTIs, bladder stones, urinary retention, and eventually bilateral hydronephrosis and CKD.

Medical treatment (alpha-blockers: tamsulosin, silodosin; 5-alpha reductase inhibitors: finasteride, dutasteride) reduces symptoms in mild to moderate BPH. Surgical treatment for significant obstruction or failed medical therapy: HoLEP (holmium laser enucleation of the prostate — the gold standard at KIMS — effective for all prostate sizes with no size limit) or TURP (transurethral resection).

Bladder cancer is the most common cancer of the urinary tract and the fourth most common cancer in men globally. The majority (90%) are urothelial (transitional cell) carcinomas. Risk factors include smoking (the most important modifiable risk factor — carcinogens in tobacco concentrate in the urine), occupational exposure (aromatic amines in dye, rubber, and chemical industries), cyclophosphamide chemotherapy, and schistosomiasis (relevant in parts of Africa). Painless haematuria (blood in the urine) is the cardinal symptom.

Non-muscle invasive bladder cancer (NMIBC — 75 to 80% of cases) is managed endoscopically with TUR-BT, intravesical BCG, and lifelong cystoscopy surveillance. Muscle-invasive bladder cancer (MIBC) requires radical cystectomy (robotic at KIMS using Da Vinci Xi) with urinary diversion. Metastatic disease is treated with platinum-based chemotherapy and immune checkpoint inhibitors.

Bladder pain syndrome (BPS) — also termed interstitial cystitis (IC) — is a chronic bladder condition causing persistent pelvic or bladder pain, urinary urgency, and frequency in the absence of any identifiable infection or other specific pathology. It is significantly more common in women (8:1 female to male ratio) and is frequently misdiagnosed as recurrent urinary tract infection despite consistently negative urine cultures. Symptoms worsen as the bladder fills and partially improve after voiding. IC/BPS significantly impairs quality of life.

Diagnosis requires exclusion of infection (three negative urine cultures) and cystoscopy under anaesthesia — which identifies Hunner lesions (inflammatory patches in approximately 10 to 15% of IC patients, treatable by fulguration). Treatment is multimodal: dietary modification (avoiding acidic and caffeinated foods), amitriptyline, pentosan polysulfate sodium, intravesical DMSO, and neuromodulation for refractory cases.

C3 glomerulopathy is a complement-driven glomerular disease caused by dysregulation of the alternative complement pathway — leading to C3 deposition in the glomeruli without significant immunoglobulin. C3G encompasses C3 glomerulonephritis (C3GN) and Dense Deposit Disease (DDD — formerly MPGN Type II). It presents with haematuria, proteinuria, low serum C3 (with normal C4), and progressive CKD. On immunofluorescence, dominant C3 staining (above 2+) with absent or trace immunoglobulin distinguishes C3G from immune complex MPGN.

Diagnosis requires kidney biopsy with full IF and EM — EM distinguishes C3GN (mesangial and subendothelial deposits) from DDD (highly electron-dense intramembranous deposits — the zebra stripe appearance). Complement workup includes C3 nephritic factor (C3NeF), anti-Factor H antibody, and genetic complement panel. Treatment: ACE inhibitors, mycophenolate, and eculizumab for refractory cases. High recurrence rate in transplant.

Cardiorenal syndrome (CRS) describes the bidirectional pathological interaction between the heart and kidneys — where dysfunction of one organ causes or worsens dysfunction of the other. Five types: acute cardiac causing AKI (Type 1), chronic cardiac causing CKD (Type 2), acute kidney causing cardiac dysfunction (Type 3), chronic kidney causing cardiac disease (Type 4), and systemic disease causing both (Type 5). CKD is the leading cause of cardiovascular death — cardiovascular disease is the leading cause of death in CKD.

The SGLT2 inhibitors (dapagliflozin, empagliflozin) represent the most important recent advance — they simultaneously slow CKD progression, reduce hospitalisation for heart failure, and reduce cardiovascular mortality in both diabetic and non-diabetic CKD with heart failure. Management requires joint nephrology and cardiology expertise — a model available at KIMS.

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function persisting for more than 3 months — classified by eGFR (Stage 1 above 90, Stage 2 60–89, Stage 3a 45–59, Stage 3b 30–44, Stage 4 15–29, Stage 5 below 15 ml/min/1.73m²) and by the degree of albuminuria (ACR). India has over 100 million people with CKD — one of the largest CKD burdens in the world — driven by diabetes, hypertension, and glomerulonephritis. The majority of CKD is asymptomatic until Stage 3 to 4.

Kidney-protective therapy: ACE inhibitors or ARBs (reduce albuminuria and slow eGFR decline), SGLT2 inhibitors (reduce eGFR decline and cardiovascular events — proven in multiple RCTs across all causes of CKD), blood pressure control (target below 130/80 mmHg), dietary protein moderation, smoking cessation. At KIMS, CKD is managed with a comprehensive multidisciplinary protocol addressing all modifiable progression factors.

CAKUT is the collective term for structural developmental abnormalities of the kidneys and urinary tract — the most common cause of CKD in children and young adults, responsible for approximately 30 to 50% of ESRD in patients below 25 years. CAKUT includes: renal agenesis (one or both kidneys absent), duplex kidney (two collecting systems), horseshoe kidney, ureteropelvic junction obstruction, posterior urethral valve, vesicoureteral reflux, ureterocele, ectopic ureter, and multicystic dysplastic kidney.

Many CAKUT conditions are detected antenatally on foetal ultrasound. Management depends on the specific anomaly — some require immediate surgical correction (PUV, significant UPJ obstruction), others are observed with serial imaging and functional assessment (mild VUR, unilateral hydronephrosis). At KIMS, the Paediatric Renal Centre coordinates nephrology and urology assessment for all CAKUT.

Conn's syndrome (primary hyperaldosteronism) is the most common cause of secondary hypertension — accounting for 5 to 10% of hypertensive adults and up to 20% of those with resistant hypertension (blood pressure uncontrolled on 3 or more drugs). Excess aldosterone from the adrenal gland causes sodium retention, potassium wasting (hypokalaemia), and RAAS-independent hypertension. It is caused by a unilateral aldosterone-producing adenoma (APA — surgical cure by adrenalectomy) or bilateral adrenal hyperplasia (medical treatment with spironolactone or eplerenone).

Screening: aldosterone-to-renin ratio (ARR) in all patients with resistant hypertension, hypokalaemia with hypertension, or hypertension with an adrenal mass. Adrenal vein sampling (AVS) distinguishes unilateral from bilateral disease before surgery. At KIMS, robotic adrenalectomy for APA achieves blood pressure cure in 35 to 70% of patients and significantly reduces the cardiovascular damage driven by excess aldosterone.

Contrast-induced AKI (CI-AKI) is deterioration in kidney function within 24 to 72 hours of IV iodinated contrast administration (for CT or angiography), defined as a creatinine rise of 44 µmol/L or more or a 25% increase from baseline. The true risk in patients with eGFR above 45 ml/min is low (below 1%). Risk rises sharply with pre-existing CKD (especially below 30 ml/min), diabetes, volume depletion, high contrast volume, and concurrent nephrotoxins.

Prevention: adequate IV hydration with 0.9% saline before and after contrast (the most effective measure), low-osmolar or iso-osmolar contrast agents, minimum effective contrast volume, withholding NSAIDs and nephrotoxins before the procedure. Metformin should be withheld for 48 hours after contrast in patients with eGFR below 45 ml/min. At KIMS, high-risk patients (eGFR below 45) are reviewed by nephrology before contrast procedures.

Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, leading to accumulation of the amino acid cystine within lysosomes of all cells. Kidney involvement is the most significant: proximal tubular dysfunction (Fanconi syndrome — loss of glucose, amino acids, phosphate, potassium, and bicarbonate) causes growth retardation, rickets, polyuria, and polydipsia in infancy. Without treatment, ESRD develops by age 10 to 12 years. Cystine also accumulates in the cornea (corneal crystals visible on slit-lamp — pathognomonic), thyroid, muscle, and brain.

Diagnosis: elevated leukocyte cystine level (the definitive test), CTNS gene mutation analysis. Treatment: cysteamine (Cystagon or Procysbi) — a cystine-depleting agent that removes cystine from lysosomes, dramatically slowing kidney disease progression and preventing systemic cystine accumulation. Started as early as possible and continued lifelong. Kidney transplant for ESRD — the transplanted kidney does not develop cystinosis, but cysteamine must be continued for systemic cystinosis.

Cystinuria is a hereditary defect in the renal tubular reabsorption of the amino acids cystine, ornithine, lysine, and arginine (COLA) — caused by mutations in the SLC3A1 or SLC7A9 genes. Cystine is poorly soluble in urine and precipitates to form cystine kidney stones — characteristically large, staghorn, recurrent, and bilateral. Cystine stones account for approximately 1% of all kidney stones in adults but up to 6 to 8% of stones in children. They have a distinctive flat-topped hexagonal crystal appearance on urine microscopy.

Diagnosis: 24-hour urine cystine quantification (above 250 mg/day in homozygotes) and urine microscopy for hexagonal cystine crystals. Treatment: very high fluid intake (above 3 litres/day — maintaining urine output above 2 litres minimises cystine concentration), urine alkalinisation with potassium citrate (cystine solubility increases dramatically at pH above 7.5), and D-penicillamine or tiopronin (bind cystine and form more soluble mixed disulphides) for heavy stone formers. RIRS and PCNL for stone clearance at KIMS.

A cystocele is a herniation of the bladder into the vaginal canal — caused by weakness of the pubocervical fascia (the connective tissue between the bladder and vagina) from vaginal childbirth, ageing, or oestrogen deficiency. It is the most common form of pelvic organ prolapse. Graded I to IV by the POP-Q system — from minimal (Grade I, into the upper vagina) to complete (Grade IV, beyond the vaginal opening). Symptoms include pelvic pressure, a bulge at the vaginal opening, incomplete bladder emptying, recurrent UTIs, and urinary incontinence.

Conservative management: pelvic floor muscle training (supervised physiotherapy) and vaginal pessary for mild to moderate cases. Surgical correction: anterior colporrhaphy (anterior vaginal wall repair) for Grades II to III, often combined with a mid-urethral sling for concurrent stress urinary incontinence. Pre-operative urodynamics identifies occult stress incontinence (present in 40 to 60% of women with large cystoceles) that would otherwise emerge after prolapse repair.

A renal cyst is a fluid-filled sac within or on the kidney — found in approximately 50% of people above age 50 and classified by the Bosniak system (Categories I through IV) based on CT characteristics. Bosniak Category I (simple cyst — hairline wall, no septae, no enhancement) has zero malignancy risk and requires no follow-up. Category II (minimal complexity) is also benign. Category IIF (multiple thin septae, perceived enhancement) carries 5 to 10% malignancy risk and requires 5 years of surveillance imaging. Categories III and IV have 40 to 100% malignancy risk and require MDT review and usually surgical resection.

Simple renal cysts are the most common incidental kidney finding and require no treatment. Complex cysts detected on CT or MRI require Bosniak classification by an experienced radiologist and specialist review at KIMS. Robotic partial nephrectomy (RAPN) is offered for Bosniak III and IV cysts. The Bosniak category — not the cyst size or symptoms — determines management.

Diabetic nephropathy is the most common cause of chronic kidney disease and end-stage renal disease in India — occurring in approximately 30 to 40% of patients with Type 2 diabetes and in 20 to 30% with Type 1 diabetes. It begins with glomerular hyperfiltration and microalbuminuria (ACR 3 to 30 mg/mmol — the earliest reversible stage), progresses to overt proteinuria, hypertension, and steadily declining eGFR, and — if untreated — reaches ESRD within 10 to 20 years. Diabetic nephropathy is a microvascular complication of diabetes — caused by the toxic effects of prolonged hyperglycaemia on the glomerular capillaries, producing the characteristic Kimmelstiel-Wilson nodules on kidney biopsy.

Treatment: HbA1c control below 7% (UKPDS trial — reduces microvascular complications by 25%), blood pressure below 130/80 mmHg, ACE inhibitors or ARBs (reduce proteinuria and slow CKD progression), SGLT2 inhibitors (CREDENCE and DAPA-CKD trials — reduce the composite of ESRD, eGFR decline, and death in diabetic CKD by 30 to 40%), and GLP-1 receptor agonists (semaglutide — further reduces albuminuria). Annual ACR and eGFR from the year of diabetes diagnosis.

Dysuria — painful or burning urination — is one of the most common urological symptoms, experienced by millions of Indian adults annually. The most frequent cause is urinary tract infection (UTI) — cystitis in women, urethritis in men. Other important causes include sexually transmitted infections (gonorrhoea, chlamydia — causing urethral discharge alongside dysuria), interstitial cystitis/bladder pain syndrome (dysuria with negative urine culture), urethral stricture (causing dysuria with poor urinary stream), prostatitis (in men — with perineal pain), and — less commonly — bladder cancer (particularly in older adults or those with haematuria alongside dysuria).

Evaluation: urine dipstick and microscopy, urine culture, and — in men — urethral swab for STI. Cystoscopy is warranted for any adult with persistent dysuria and negative cultures, haematuria, or risk factors for bladder cancer. At KIMS, dysuria that does not resolve with standard antibiotic treatment is evaluated systematically to exclude structural, neoplastic, and inflammatory causes.

Oedema — the accumulation of excess fluid in the body tissues, visible as swelling of the ankles, legs, face, and abdomen — is a symptom, not a diagnosis. The underlying cause determines both the severity and the correct treatment. Kidney-related causes include nephrotic syndrome (heavy proteinuria reduces serum albumin, lowering oncotic pressure and causing fluid to leak into tissues) and advanced CKD (sodium and water retention from reduced kidney excretory capacity). Non-renal causes include cardiac failure, liver cirrhosis, venous insufficiency, and — commonly in India — drug side effects (particularly amlodipine-induced ankle oedema).

Periorbital oedema (puffiness around the eyes on waking) is the most specific sign of nephrotic syndrome. Abdominal swelling (ascites) combined with leg oedema suggests either hepatic or nephrotic origin. Rapidly developing generalised oedema with frothy urine requires urgent nephrological evaluation — serum albumin, urine ACR, and echocardiography identify the cause. At KIMS, the principle is 'find the cause, not just the symptom' — treating oedema without diagnosing its origin is temporary at best.

Emphysematous pyelonephritis (EPN) is a life-threatening necrotising gas-forming infection of the kidney — occurring almost exclusively in patients with diabetes mellitus. Gas-producing Gram-negative bacteria (typically E. coli or Klebsiella) infect the poorly perfused diabetic kidney, producing gas within the renal parenchyma, perinephric space, and — in severe cases — the retroperitoneum. It is classified by CT severity (Grades I to IV) — Grade IV (bilateral EPN or EPN with urinary obstruction and extension into the retroperitoneum) has a mortality above 40 to 50% without aggressive management.

CT of the abdomen confirms the diagnosis — gas within the kidney is diagnostic. Management: aggressive IV antibiotics, blood glucose control (diabetic emergency management), percutaneous drainage of gas and fluid collections, and — for severe Grade III and IV disease — emergency nephrectomy. Nephrectomy combined with antibiotics reduces mortality from above 80% (antibiotics alone) to approximately 20%. At KIMS, emphysematous pyelonephritis is managed as a urological and diabetological emergency.

Epididymitis — inflammation of the epididymis — is the most common cause of scrotal pain in adult men above 35, while testicular torsion is the most important differential in younger men and adolescents. In men below 35, epididymitis is most commonly caused by sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae). In men above 35, it is caused by Gram-negative enteric bacteria (E. coli, Klebsiella) in association with BPH or urinary tract instrumentation. In India, genitourinary tuberculosis is an important cause of chronic, painless epididymal swelling.

Diagnosis: scrotal Doppler ultrasound (shows increased blood flow to the epididymis in epididymitis, distinguishing it from testicular torsion where blood flow to the testicle is absent). Urine culture and STI NAAT testing. TB workup for chronic presentations. Treatment: doxycycline + ceftriaxone for STI-related; ciprofloxacin for enteric; 6-month anti-TB regimen for TB epididymitis. Any acute scrotal pain must exclude torsion by urgent Doppler — at KIMS, scrotal Doppler is available 24/7.

Erectile dysfunction (ED) — the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity — affects approximately 10 to 30% of adult men in India. It is a multifactorial condition with organic (vascular, neurogenic, hormonal) and psychogenic components. ED is an important marker of cardiovascular risk — the arterial insufficiency causing ED often precedes coronary artery disease by 2 to 5 years. Risk factors include diabetes (most important organic cause — diabetic autonomic neuropathy and vascular disease affect both the erectile mechanism and libido), hypertension, dyslipidaemia, smoking, obesity, and certain medications (antihypertensives, antidepressants).

Evaluation includes morning testosterone, glycaemic control assessment, lipid profile, and vascular risk factor review. First-line treatment: PDE5 inhibitors (sildenafil, tadalafil, vardenafil) — highly effective in 60 to 70% of organic ED. Second-line: intracavernosal injection therapy (alprostadil). Third-line: penile prosthesis implantation (for those who fail or cannot use pharmacological options). At KIMS, ED is evaluated as a marker of cardiovascular health, not just as an isolated sexual problem.

Fabry disease is an X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A — leading to accumulation of glycosphingolipid Gb3 in the kidneys, heart, peripheral nerves, and blood vessels. It causes progressive kidney disease (proteinuria → CKD → ESRD by the 4th to 5th decade in untreated males), hypertrophic cardiomyopathy, stroke, and neuropathic pain. Corneal verticillata (whorled corneal opacities on slit-lamp) are pathognomonic. Diagnosis: leukocyte alpha-GalA enzyme activity (low in males), GLA gene sequencing (required for females), plasma lyso-Gb3.

Kidney biopsy shows pathognomonic 'zebra bodies' on electron microscopy — multilamellar lysosomal inclusions in podocytes and tubular cells. Treatment: enzyme replacement therapy (agalsidase alfa or agalsidase beta — IV every 2 weeks) slows kidney, cardiac, and neurological progression when started before advanced organ damage. Migalastat (oral pharmacological chaperone) for patients with amenable GLA mutations. At KIMS, Fabry disease is evaluated through the genetic nephrology and glomerular disease programme.

Focal segmental glomerulosclerosis (FSGS) is a histological pattern of glomerular injury — characterised by scarring (sclerosis) of portions (segmental) of some (focal) glomeruli on kidney biopsy. It is one of the most common causes of nephrotic syndrome in adults and the leading cause of primary nephrotic syndrome in Black patients. FSGS may be primary (immune-mediated, driven by a circulating permeability factor — possibly soluble urokinase receptor, suPAR), secondary (from morbid obesity, sickle cell disease, reflux nephropathy, or hyperfiltration), or genetic (mutations in podocin, nephrin, WT1, or other podocyte structural proteins).

Clinical presentation: heavy proteinuria (often nephrotic-range), hypertension, and progressive CKD. Primary FSGS often responds to corticosteroids (remission in 30 to 50%) — steroid-resistant FSGS requires calcineurin inhibitors (cyclosporine, tacrolimus) or rituximab. Secondary and genetic FSGS is managed with kidney protection (ACE inhibitors, SGLT2 inhibitors) without immunosuppression. Kidney biopsy with EM at KIMS characterises the FSGS variant and guides treatment.

Genitourinary tuberculosis is the most common form of extrapulmonary TB, accounting for 30 to 40% of extrapulmonary TB cases and representing an important clinical entity in India where TB burden remains the highest in the world. GUTB arises from haematogenous spread of M. tuberculosis from a primary pulmonary focus to the kidney, spreading downward via the urine to the ureter, bladder, prostate, epididymis, and other genitourinary organs. The kidneys are the most commonly affected organ. The pathognomonic clinical clue is sterile pyuria — white cells in the urine with a negative standard bacterial culture.

Diagnosis: early morning urine for AFB culture (three specimens — the most sensitive test), CBNAAT (Xpert MTB/RIF) on urine, CT urogram (moth-eaten calyces, ureteric strictures, autonephrectomy). Treatment: 6-month RNTCP/WHO ATT regimen. Ureteric strictures require JJ stenting during treatment. Reconstructive urology (ureteroplasty, bladder augmentation) for established strictures after completing ATT. At KIMS, GUTB is evaluated jointly by the nephrology and urology teams.

Gitelman syndrome is the most common hereditary renal tubular disorder — caused by loss-of-function mutations in the SLC12A3 gene encoding the thiazide-sensitive sodium-chloride cotransporter in the distal convoluted tubule. It causes hypokalaemia (low serum potassium), metabolic alkalosis, hypomagnesaemia, and hypocalciuria (low urinary calcium — distinguishing it from Bartter syndrome, which is associated with hypercalciuria). Most patients are diagnosed in adolescence or adulthood — presenting with fatigue, muscle cramps, paraesthesias, and occasional cardiac arrhythmias from hypokalaemia and hypomagnesaemia. Blood pressure is normal or low.

Gitelman syndrome is a chronic, manageable condition — not a progressive kidney disease. Treatment: lifelong potassium and magnesium supplementation (oral potassium chloride and magnesium chloride or glycerophosphate). Potassium-sparing diuretics (spironolactone, amiloride) can reduce urinary potassium wasting. Indomethacin may help in selected cases. At KIMS, Gitelman syndrome is distinguished from Bartter syndrome, hypokalaemia from laxative use, and primary hyperaldosteronism by the combination of normal blood pressure, metabolic alkalosis, hypomagnesaemia, and hypocalciuria.

Glomerulonephritis (GN) is inflammation of the glomeruli — the filtering units of the kidney — causing haematuria (blood in the urine, often with red cell casts on microscopy confirming glomerular origin), proteinuria, hypertension, and declining kidney function. GN is classified by the clinical syndrome it produces — nephritic (haematuria, hypertension, proteinuria, reduced GFR: typical of IgA nephropathy, post-infectious GN, ANCA vasculitis) or nephrotic (heavy proteinuria, hypoalbuminaemia, oedema: typical of membranous nephropathy, MCD, FSGS). Rapidly progressive GN (RPGN) — GFR halving within weeks — is an emergency.

Kidney biopsy with light microscopy, immunofluorescence, and electron microscopy (all performed in-house at KIMS's NABL-accredited laboratory) identifies the specific GN pattern — which determines both prognosis and treatment. The specific glomerulonephritides covered by dedicated KIMS condition pages include IgA nephropathy, membranous nephropathy, ANCA vasculitis, lupus nephritis, Goodpasture syndrome, C3 glomerulopathy, and post-infectious GN.

Goodpasture syndrome is an autoimmune disease characterised by anti-glomerular basement membrane (anti-GBM) antibodies that attack both the renal GBM and the pulmonary alveolar basement membrane — causing the simultaneous combination of rapidly progressive glomerulonephritis and pulmonary haemorrhage (pulmonary-renal syndrome). Without treatment, renal failure progresses to dialysis within days to weeks, and massive pulmonary haemorrhage can be immediately fatal. Anti-GBM antibody titre correlates with disease activity. Kidney biopsy shows crescentic GN with linear IgG deposition on immunofluorescence — the pathognomonic pattern of anti-GBM disease.

Treatment is a true emergency: plasma exchange (removes the circulating anti-GBM antibodies), high-dose prednisolone, and cyclophosphamide (suppresses further antibody production) must be started immediately — delay of even 24 to 48 hours significantly worsens kidney outcome. Kidney recovery is poor when creatinine is above 500 µmol/L or dialysis is already required at presentation — aggressive early treatment is the only window for renal salvage. At KIMS, suspected Goodpasture syndrome triggers an emergency nephrology pathway with 24/7 plasma exchange availability.

Gross haematuria — visibly blood-tinged or red-coloured urine — is one of the most important urological symptoms, requiring systematic investigation regardless of whether it is painful (common with stones or UTI) or painless (more concerning for malignancy). Painless gross haematuria is the cardinal symptom of both bladder cancer and upper tract urothelial carcinoma — and must be investigated with CT urogram and cystoscopy in any adult above 40, even if it resolves spontaneously between investigations. Haematuria from a single episode that resolves does not exclude cancer.

Investigation protocol for adults with gross haematuria: midstream urine culture and sensitivity; urine cytology; CT urogram (non-contrast + nephrographic + excretory phases — identifies stones, renal masses, and upper tract filling defects); flexible cystoscopy. Common causes: UTI, kidney stones, bladder cancer, upper tract tumour, BPH, glomerulonephritis (red cell casts on microscopy confirm glomerular origin), anticoagulant medications. At KIMS, any adult presenting with gross haematuria is offered a same-week urology appointment.

Haematospermia — blood in the ejaculate — is alarming to men but is most commonly benign and self-limiting, particularly in men below 40. The most common cause is inflammation or infection of the seminal vesicles or prostate (seminal vesiculitis, prostatitis). Other causes include posterior urethral instrumentation (post-cystoscopy, post-biopsy), calculi in the ejaculatory duct, and — rarely — seminal vesicle or prostate tumour. In men above 40, haematospermia warrants more thorough investigation including PSA and transrectal ultrasound (TRUS) to exclude prostate pathology.

Most haematospermia below age 40 resolves spontaneously within 4 to 6 weeks without treatment. Investigation: urine culture and STI screening for infective causes, PSA for men above 40. Scrotal and TRUS ultrasound if persistent beyond 3 to 4 months or associated with other urinary symptoms. Reassurance and observation are appropriate in most young men with isolated haematospermia. At KIMS, haematospermia is assessed in the andrology and urology outpatient service.

Microscopic haematuria is the presence of red blood cells in the urine detectable only on dipstick or microscopy — not visible to the naked eye. Defined as 3 or more red blood cells per high-power field on microscopic analysis of a freshly centrifuged midstream urine specimen. It is a common incidental finding — occurring in approximately 2 to 13% of the adult population — and requires systematic evaluation to exclude significant underlying pathology. Causes range from benign (exercise-induced, mild infection, menstrual contamination) to serious (bladder cancer, upper tract tumour, renal parenchymal disease).

Any adult above 40 with confirmed microscopic haematuria (on two of three urine specimens) should have CT urogram and cystoscopy — particularly if associated with risk factors (smoking, chemical exposure, prior pelvic radiation, analgesic abuse). Dysmorphic red cells and red cell casts on urine microscopy indicate glomerular origin, warranting nephrological evaluation including serum creatinine, urine ACR, complement levels, and ANCA. At KIMS, the structured haematuria assessment pathway covers both urological and nephrological causes.

Hepatorenal syndrome is a form of acute kidney injury occurring in patients with advanced liver cirrhosis or acute liver failure — in which kidney failure is functional (driven by extreme renal vasoconstriction from splanchnic vasodilation) rather than structural. The kidneys themselves are normal — if the liver were transplanted or the haemodynamic condition reversed, the kidneys would recover. HRS-AKI (formerly Type 1) is rapidly progressive (median untreated survival 2 to 4 weeks). HRS-CKD (formerly Type 2) is slower and associated with refractory ascites.

Treatment: terlipressin (a vasopressin analogue that constricts splanchnic vessels, improving renal perfusion) combined with IV albumin — the first-line treatment for HRS-AKI, achieving response (creatinine returning to baseline) in 40 to 50% of cases. CRRT supports the patient while terlipressin and albumin take effect. Liver transplantation is the only definitive cure — the kidneys recover after successful liver transplant. At KIMS, CRRT is available 24/7 for HRS management.

Horseshoe kidney is the most common renal fusion anomaly — occurring in approximately 1 in 500 people — in which the two kidneys are fused at their lower poles during embryological development, forming a continuous horseshoe-shaped structure that sits lower than normal in the abdomen (at L3 to L4 rather than T12 to L2). The inferior mesenteric artery catches the isthmus and prevents normal ascent. Most horseshoe kidneys are asymptomatic — discovered incidentally on abdominal imaging. The abnormal anatomy predisposes to: ureteropelvic junction obstruction (from the high ureteric insertion over the isthmus), kidney stones (from impaired drainage), and recurrent UTIs.

Horseshoe kidneys also have a modestly elevated risk of certain tumours: transitional cell carcinoma (3 to 4 times the normal rate) and Wilms' tumour in children. Annual renal ultrasound surveillance is recommended for all adults with horseshoe kidney to detect stones and tumours. Robotic pyeloplasty at KIMS for symptomatic PUJ obstruction, and CT-guided Mini-PCNL for the complex stone anatomy of horseshoe kidneys.

A hydrocele is an accumulation of serous fluid between the two layers of the tunica vaginalis — the thin membrane surrounding the testicle — producing a smooth, painless swelling of the scrotum. It is the most common cause of painless scrotal swelling, occurring in 1 to 2% of all male neonates (congenital hydrocele, from a patent processus vaginalis) and as an acquired condition in adults (following epididymo-orchitis, testicular torsion, trauma, or — in tropical regions — lymphatic filariasis). Hydroceles transilluminate (a torch shone through the swelling in a dark room passes through the fluid).

Congenital hydroceles in infants typically resolve spontaneously by 12 to 18 months as the processus vaginalis closes. Persistence beyond 18 months or recurrence of a previously resolved hydrocele requires surgical repair (hydrocelectomy — eversion or excision of the tunica vaginalis). Any adult with a new hydrocele should have scrotal ultrasound to exclude testicular cancer as an underlying cause. At KIMS, hydrocele repair is performed as a day-case under general anaesthesia.

Hydronephrosis is the dilation of the renal pelvis and calyces — caused by obstruction of urine flow from the kidney. It is a radiological finding (identified on ultrasound or CT) rather than a diagnosis — the underlying cause of the obstruction must be identified and treated. Common causes: ureteric stones (the most common cause of acute unilateral hydronephrosis in India), UPJ obstruction (congenital or acquired), tumour compressing the ureter, BPH or bladder outlet obstruction (causing bilateral hydronephrosis), posterior urethral valve (in male infants), and — during pregnancy — physiological hydronephrosis of the right kidney from uterine compression.

The functional significance of hydronephrosis is assessed by the degree of dilation (graded I to IV by SFU system) and — critically — by the DTPA renogram, which measures differential kidney function and drainage. A mildly dilated kidney with preserved function and good drainage may be observed. Significant obstruction with declining function requires intervention — JJ stenting, percutaneous nephrostomy, or definitive surgery (pyeloplasty, stone removal). At KIMS, all newly diagnosed hydronephrosis is evaluated with the appropriate functional investigation.

Hyperkalemia — serum potassium above 5.5 mEq/L — is potentially life-threatening because elevated potassium destabilises the cardiac membrane potential, causing the progressive ECG changes of hyperkalemia (peaked T waves, widened QRS, sine wave pattern) and ultimately fatal ventricular fibrillation. It is the most common electrolyte emergency in nephrology, occurring most frequently in patients with advanced CKD (where the kidneys cannot excrete the daily dietary potassium load), AKI, and in patients taking ACE inhibitors, ARBs, or potassium-sparing diuretics.

Emergency management follows a five-step approach: (1) IV calcium gluconate (membrane stabilisation within minutes), (2) insulin-dextrose + nebulised salbutamol + IV bicarbonate (shift potassium into cells — lowers serum K+ by 0.5 to 1.5 mEq/L within 15 to 30 minutes), (3) patiromer or sodium zirconium cyclosilicate (remove potassium from the body via the gut), (4) furosemide (if residual kidney function allows), and (5) haemodialysis for refractory or severe hyperkalemia. At KIMS, ECG monitoring and emergency nephrology are available 24/7.

Hyperoxaluria — excess urinary oxalate excretion above 40 mg/day — is an important cause of recurrent calcium oxalate kidney stones, nephrocalcinosis, and oxalate nephropathy. Three types: primary hyperoxaluria (PH1, PH2, PH3 — inborn errors of metabolism causing massive endogenous oxalate overproduction, typically presenting in childhood with severe bilateral stone disease and systemic oxalosis), enteric hyperoxaluria (increased oxalate gut absorption from fat malabsorption — after bariatric surgery, Crohn's disease, or ileal resection), and dietary hyperoxaluria (excessive intake of high-oxalate foods — spinach, nuts, tea, chocolate).

PH1 treatment: pyridoxine (B6) for responsive cases, high fluid intake, potassium citrate, and — the most recent advance — lumasiran (RNA interference therapy that silences hepatic glyoxylate production, reducing oxalate synthesis by up to 65%). Combined liver-kidney transplant for PH1 with ESRD — the liver harbours the enzyme defect, so liver transplant alone with kidney transplant provides the definitive cure. At KIMS, 24-hour urine oxalate, genetic testing for PH1/2/3, and metabolic stone clinic assessment are all available.

Hypospadias is a congenital condition in which the urethral meatus is located on the ventral (underside) surface of the penis, rather than at the tip of the glans — occurring in approximately 1 in 200 to 300 male births. Severity ranges from mild (glanular — just below the tip) to severe (penoscrotal or perineal). Associated anomalies include chordee (ventral penile curvature from the urethral plate remnant) and undescended testicle (present in approximately 9% of cases). Hypospadias causes a downward-directed urinary stream (preventing standing urination in moderate and severe forms) and — in adult life without repair — may impair sexual function from penile curvature.

Surgical correction (urethroplasty) is recommended between 6 and 18 months of age — the optimal window combining best tissue-to-instrument ratio, pre-language psychology, and testosterone-stimulated penile size. The foreskin — which is incomplete in hypospadias (dorsal hood only) — must be preserved as reconstructive material; circumcision before specialist assessment destroys this tissue permanently. At KIMS, the TIP (Snodgrass) repair is used for distal and mid-shaft hypospadias; two-stage buccal mucosa urethroplasty for proximal cases.

Hypertension and kidney disease are so closely intertwined that each is both a cause and a consequence of the other. Chronic hypertension causes hypertensive nephrosclerosis — fibrosis of the renal arterioles and interstitium — leading to CKD. Conversely, CKD from any cause activates the RAAS, promotes sodium retention, and causes hypertension through multiple mechanisms. Approximately 80% of patients with CKD Stage 3 and above have hypertension. Malignant hypertension (blood pressure above 180/120 with end-organ damage) can cause rapidly progressive AKI from fibrinoid arteriolar necrosis.

Target blood pressure in CKD: below 130/80 mmHg, or below 125/75 mmHg when proteinuria exceeds 1 gram per day. ACE inhibitors and ARBs are the preferred antihypertensives in CKD — they reduce proteinuria and slow CKD progression independently of their blood pressure-lowering effect. SGLT2 inhibitors further reduce blood pressure and CKD progression. Dietary sodium restriction (below 2g/day) is a fundamental non-pharmacological measure.

Hypocalcaemia — serum calcium below 2.1 mmol/L (corrected for albumin) — is common in CKD from two mechanisms: impaired renal activation of vitamin D (the kidney converts 25-OH vitamin D to the active 1,25-OH calcitriol, which drives intestinal calcium absorption) and phosphate retention (elevated phosphate suppresses calcitriol and promotes calcium-phosphate complex formation). Symptoms: perioral tingling, muscle cramps, tetany (Chvostek and Trousseau signs), and — in severe cases — seizures and laryngospasm. Hypocalcaemia after parathyroidectomy ('hungry bone syndrome') can be severe and prolonged.

In CKD, hypocalcaemia is managed with activated vitamin D (alfacalcidol or calcitriol — supplementing the missing renal activation step) and calcium carbonate (as a phosphate binder that also provides calcium). In acute severe hypocalcaemia (tetany, seizures): IV calcium gluconate 10% solution. Magnesium deficiency must be corrected simultaneously — hypomagnesaemia prevents PTH secretion and causes refractory hypocalcaemia. At KIMS, calcium monitoring is part of the standard CKD-MBD blood panel.

Hyponatraemia — serum sodium below 135 mEq/L — is the most common electrolyte disorder in hospitalised patients, affecting 15 to 30% of inpatients. It is caused by excess water retention relative to sodium — almost always from excessive antidiuretic hormone (ADH) activity. Classification by volume status guides treatment: hypovolaemic hyponatraemia (sodium and water both lost, but more water retained — treat with IV normal saline), euvolaemic hyponatraemia (SIADH — the most common cause overall — treat with fluid restriction and tolvaptan), and hypervolaemic hyponatraemia (cardiac failure, cirrhosis, nephrotic syndrome — treat the underlying condition).

The most critical treatment principle: sodium must not be raised more than 8 to 10 mEq/L in any 24-hour period in chronic hyponatraemia — faster correction causes osmotic demyelination syndrome (ODS), an irreversible brainstem injury causing quadriplegia and locked-in syndrome. Acute symptomatic hyponatraemia (seizures, coma) is treated with 100ml boluses of hypertonic (3%) saline. Tolvaptan (vasopressin V2 receptor antagonist) corrects SIADH but must be initiated in a monitored inpatient setting at KIMS.

IgA nephropathy (Berger's disease) is the most common primary glomerulonephritis worldwide — caused by mesangial deposition of galactose-deficient IgA1 immune complexes, triggering mesangial inflammation and progressive glomerular damage. It classically presents with episodic gross haematuria coinciding with upper respiratory tract infections (synpharyngitic haematuria — occurring simultaneously with the infection, distinguishing it from post-infectious GN where haematuria appears 1 to 3 weeks later). Microscopic haematuria and proteinuria are persistent between episodes. The Oxford MEST-C scoring system on biopsy guides prognosis.

Management: ACE inhibitors or ARBs for proteinuria reduction and blood pressure control. SGLT2 inhibitors (sparsentan is a specific dual endothelin-angiotensin receptor antagonist approved for IgA nephropathy). Immunosuppression (prednisolone + mycophenolate) for high-risk IgA nephropathy with proteinuria above 1 g/day despite optimised RAAS blockade. Targeted-release budesonide (Nefecon — deposited in the Peyer's patches where IgA abnormalities originate) is an emerging specific therapy. Tonsillectomy is debated — may reduce haematuria episodes in some patients.

IgG4-related kidney disease is the renal manifestation of IgG4-related disease (IgG4-RD) — a systemic fibroinflammatory condition affecting multiple organs including the kidneys, pancreas, salivary glands, bile ducts, and retroperitoneum. Kidney involvement occurs in two patterns: IgG4-related tubulointerstitial nephritis (IgG4-TIN — the most common, characterised by dense IgG4-positive plasma cell infiltration and storiform fibrosis in the interstitium, causing declining eGFR with mild proteinuria) and IgG4-related membranous nephropathy (causing nephrotic syndrome).

Serum IgG4 is elevated in 60 to 70% of active cases. Kidney biopsy with IgG4 immunostaining (more than 10 IgG4-positive plasma cells per high-power field, IgG4/total IgG ratio above 40%) confirms the diagnosis. The diagnostic and therapeutic 'steroid test' — a dramatic improvement in eGFR within 4 to 8 weeks of prednisolone — characterises IgG4-TIN. Rituximab for steroid-dependent or refractory cases. Early treatment (before fibrosis is established) gives the best eGFR recovery.

Urinary incontinence — the involuntary leakage of urine — affects an estimated 200 to 400 million people worldwide, with significantly higher prevalence in women. The three main types require different evaluation and treatment: stress urinary incontinence (SUI — leakage with coughing, sneezing, or exercise, from inadequate urethral sphincter support — typically from vaginal childbirth or oestrogen deficiency), urgency urinary incontinence (UUI — sudden, irresistible urge to void followed by leakage, from involuntary detrusor contractions — the 'overactive bladder' pattern), and mixed incontinence (both components).

Pelvic floor muscle training (PFMT) supervised by a physiotherapist is the first-line treatment for both SUI and UUI — effective in 50 to 70% of patients when performed correctly. For SUI not responding to PFMT, mid-urethral sling surgery (TVT or TOT) achieves 80 to 90% cure. For OAB/UUI, anticholinergic medications (oxybutynin, tolterodine) or beta-3 agonists (mirabegron) provide pharmacological control. Sacral neuromodulation for refractory OAB. At KIMS, urodynamic study identifies the predominant mechanism before treatment.

Acute tubulointerstitial nephritis (AIN) is an important and often missed cause of acute kidney injury — characterised by inflammation of the renal interstitium and tubules, with relative sparing of the glomeruli. The most common causes in India: drug-induced AIN (NSAIDs, antibiotics — particularly beta-lactams, fluoroquinolones, rifampicin, PPIs — and allopurinol), and immune-mediated AIN from sarcoidosis, IgG4-related disease, or Sjögren's syndrome. Idiopathic AIN (including TINU syndrome — tubulointerstitial nephritis and uveitis) is increasingly recognised.

Classic presentation: AKI with relatively little proteinuria, bland urine sediment (occasional white cell casts), eosinophilia, eosinophiluria, skin rash, and fever — the classic drug hypersensitivity triad (fever, rash, eosinophilia) is present in only 10 to 15% of drug-induced AIN. Diagnosis: kidney biopsy confirms interstitial inflammation without glomerulonephritis. Treatment: remove the causative drug, treat the underlying condition. Prednisolone for drug-induced AIN not recovering within 2 to 4 weeks of drug cessation. Early treatment gives the best eGFR recovery.

Renal cell carcinoma (RCC) is the most common malignancy of the kidney — accounting for approximately 2 to 3% of all adult cancers, with the incidence rising due to increasing CT scan use detecting smaller incidental tumours. The classic triad (flank pain, haematuria, abdominal mass) is now rarely seen — most RCC is detected incidentally on CT. Risk factors: smoking (doubles RCC risk), obesity, hypertension, and end-stage renal disease (particularly with acquired cystic kidney disease). Clear cell RCC (70 to 75% of cases) is the most common subtype; papillary and chromophobe are less common.

Treatment for localised RCC: robotic partial nephrectomy (RAPN — kidney-sparing, preferred for T1 tumours below 7cm) or radical nephrectomy for larger lesions. Active surveillance for very small masses (below 1.5 to 2cm) in elderly or frail patients. Metastatic RCC: first-line with nivolumab + ipilimumab (immunotherapy combination) or sunitinib/pazopanib (tyrosine kinase inhibitors). At KIMS, all renal masses are reviewed at the MDT tumour board before treatment planning.

Kidney stones (nephrolithiasis) affect approximately 12% of men and 6% of women in India during their lifetime — with southern and western India having particularly high prevalence in the 'stone belt.' Calcium oxalate stones are the most common type (70 to 80%). Other types: calcium phosphate (associated with Type 1 RTA, primary hyperparathyroidism, MSK), uric acid (associated with gout, diabetes, high purine diet — radiolucent on plain X-ray), struvite (infection stones from urea-splitting bacteria — rapidly growing, staghorn), and cystine (from cystinuria — hexagonal crystals, large recurrent bilateral stones).

Management: stones below 5mm pass spontaneously with hydration and alpha-blocker (tamsulosin). Stones 5 to 10mm: ESWL or ureteroscopy (RIRS) at KIMS. Stones above 10mm or complex: Mini-PCNL at KIMS — India's pioneer PCNL centre. Metabolic evaluation (24-hour urine collection) for all recurrent stone formers identifies treatable causes (hyperoxaluria, hypercalciuria, hypocitraturia, RTA). At KIMS, stone surgery uses 100W+ holmium and TFL laser for complete stone clearance.

Loin pain haematuria syndrome (LPHS) is a diagnosis of exclusion — characterised by recurrent or persistent unilateral or bilateral loin pain with microscopic or macroscopic haematuria, in the absence of any identifiable pathological cause on standard investigation (no stones, no tumour, no glomerulonephritis, no obstruction, no infection). It disproportionately affects young women. The mechanism is incompletely understood — abnormal intrarenal coagulation, complement activation on red cell surfaces, and altered pain processing pathways have all been proposed.

Investigation protocol: CT KUB (exclude stones and structural causes), urine culture, urine microscopy with red cell morphology (dysmorphic red cells suggest glomerular origin — warranting kidney biopsy), creatinine, complement levels. If all investigations are negative, kidney biopsy may show thin basement membrane nephropathy (benign familial haematuria) or non-specific changes. Treatment is symptomatic — analgesics, calcium channel blockers (nifedipine reduces intrarenal vascular spasm in selected cases), and — for refractory severe cases — autotransplantation (kidney transplanted to the iliac fossa to interrupt renal denervation) as a last resort. At KIMS, LPHS is evaluated through the nephrology and urology outpatient programme.

Low testosterone (hypogonadism) affects approximately 20 to 30% of men above 60 in India — though it is significantly under-diagnosed because its symptoms (fatigue, low libido, reduced muscle mass, mood changes, poor concentration) are non-specific and commonly attributed to ageing or overwork without a fasting morning testosterone being measured. Hypogonadism is classified as primary (testicular failure — high LH and FSH) or secondary (hypothalamic-pituitary failure — low or inappropriately normal LH and FSH). Secondary causes include obesity, opioid use, pituitary adenoma (particularly prolactinoma), and anabolic steroid use.

Diagnosis: two fasting morning testosterone measurements below 8 nmol/L (231 ng/dL). Full hormonal workup: LH, FSH, prolactin. Treatment: testosterone replacement therapy (TRT) in available formulations — injectable testosterone undecanoate (Nebido — every 10 to 14 weeks), testosterone enanthate (every 2 to 4 weeks), or daily testosterone gel. Clomiphene citrate or hCG for men who desire fertility preservation (exogenous TRT suppresses spermatogenesis). PSA and haematocrit monitoring every 3 to 6 months on TRT. At KIMS, TRT is offered with a confidential andrology consultation.

Lupus nephritis (LN) is glomerular inflammation driven by autoimmune immune complex deposition in patients with systemic lupus erythematosus (SLE). It occurs in approximately 40 to 70% of SLE patients and is the most important determinant of long-term morbidity and mortality in SLE. LN is classified by the ISN/RPS system into six classes based on kidney biopsy findings — from minimal mesangial disease (Class I) to diffuse proliferative GN (Class IV — the most common and most severe) to membranous LN (Class V — presenting with nephrotic syndrome). The 'full house' pattern on IF (IgG + IgA + IgM + C3 + C4 + C1q all positive) is pathognomonic.

Treatment is determined by the LN class. Class III/IV (proliferative LN): induction with mycophenolate mofetil + prednisolone or cyclophosphamide + prednisolone; maintenance with mycophenolate. Belimumab (anti-BLyS monoclonal antibody) reduces LN flares. Voclosporin (calcineurin inhibitor) added to mycophenolate achieves significantly higher complete remission rates in Class III/IV/V LN. At KIMS, all LN cases are reviewed by the women's nephrology programme.

Male infertility is a contributing factor in approximately 40 to 50% of all infertile couples — and the sole cause in 20 to 30%. The primary investigation is semen analysis — evaluating sperm count (oligozoospermia: below 16 million/ml), motility (asthenozoospermia: below 42% progressive motility), and morphology (teratozoospermia: below 4% normal forms by Kruger criteria). Combined abnormalities (oligoasthenoteratozoospermia — OAT) are the most common finding. Azoospermia (no sperm) may be obstructive (from epididymal or vas deferens blockage) or non-obstructive (testicular failure — primary spermatogenic defect).

Evaluation includes: FSH, LH, testosterone, prolactin (hormonal causes), scrotal ultrasound (varicocele — the most common treatable cause, present in 35 to 40% of infertile males), and genetic analysis (karyotype, Y chromosome microdeletion) for azoospermia. Varicocele repair (microsurgical varicocelectomy) improves sperm parameters and spontaneous conception rates. Surgical sperm retrieval (PESA, TESE) with ICSI for obstructive and non-obstructive azoospermia. At KIMS, male infertility is managed in the andrology programme.

Medullary sponge kidney is a congenital (non-hereditary) structural abnormality of the renal medullary collecting ducts — which are abnormally dilated, forming tiny ectatic tubules within the medullary pyramids. These dilated ducts have impaired drainage, creating conditions for urine stasis, calcium crystallisation, and recurrent stone formation. MSK is present in 12 to 20% of patients with recurrent kidney stones. The characteristic imaging finding: 'paintbrush' or 'bouquet of flowers' appearance of contrast filling the dilated tubules during the excretory phase of CT urogram or IVU.

MSK predisposes to stones through multiple simultaneous mechanisms: urinary stasis, hypercalciuria (in 60% of MSK patients), hypocitraturia (from concurrent Type 1 RTA in 30% of cases), and recurrent UTIs. The metabolic evaluation at KIMS (24-hour urine collection — calcium, oxalate, citrate, pH) identifies all treatable abnormalities. Potassium citrate corrects concurrent RTA and hypocitraturia simultaneously. Thiazide diuretics for hypercalciuria. MSK itself is not treatable but its stone-forming complications are — metabolic evaluation is the key.

Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults above 40, characterised by subepithelial immune complex deposits on the glomerular basement membrane — causing heavy proteinuria, hypoalbuminaemia, and oedema. Primary (idiopathic) MN is caused by autoantibodies against the M-type phospholipase A2 receptor (PLA2R) on podocytes — present in 70 to 80% of primary MN cases. The anti-PLA2R antibody titre correlates with disease activity and is used for monitoring. Secondary MN is caused by hepatitis B, SLE, medications (NSAIDs, penicillamine, gold), or malignancy.

The 'rule of thirds' in primary MN: one-third achieve spontaneous complete remission, one-third have persistent proteinuria but stable eGFR, one-third progress to ESRD over 10 to 15 years. High-risk factors (persistent proteinuria above 3.5 g/day, elevated anti-PLA2R titre, declining eGFR) warrant immunosuppression: rituximab (anti-CD20 — the preferred first-line agent, targeting the B cells producing anti-PLA2R antibodies) or cyclophosphamide + prednisolone (the Ponticelli regimen). Anticoagulation for patients with serum albumin below 20 g/L (high VTE risk in MN).

Monoclonal gammopathy of renal significance (MGRS) describes kidney disease caused by a small plasma cell or B-cell clone producing a monoclonal paraprotein that deposits in or damages the kidneys — in a patient who does not meet criteria for multiple myeloma or other haematological malignancy. MGRS overturns the 'wait and watch' approach to MGUS — even a small clone causes progressive kidney destruction requiring haematological treatment. The kidney manifestations include AL amyloidosis, light chain deposition disease (LCDD), C3 glomerulopathy from complement inhibition, fibrillary GN, and immunotactoid GN.

Diagnosis requires: comprehensive paraprotein screening (SPEP + UPEP + serum free light chains), bone marrow biopsy, and kidney biopsy with LM + IF + EM — the biopsy identifies the specific deposit type and confirms that the depositing immunoglobulin matches the paraprotein clone. Treatment targets the clone (not the kidney manifestations) — bortezomib-based chemotherapy for plasma cell clones, rituximab for B-cell clones. At KIMS, every MGRS case is reviewed at the joint nephrology-haematology MDT.

Minimal change disease (MCD) is the most common cause of nephrotic syndrome in children (responsible for over 80% of paediatric nephrotic syndrome) and an important cause in adults. On light microscopy, the glomeruli appear entirely normal — hence 'minimal change.' The diagnosis requires electron microscopy to demonstrate diffuse podocyte foot process effacement (above 80% of the glomerular capillary surface) — confirming podocyte injury as the mechanism of heavy proteinuria. Immunofluorescence is negative (no immune deposits). MCD is almost always steroid-responsive — the dramatic response to corticosteroids within 4 to 8 weeks is so characteristic that it is used as a diagnostic criterion in children (biopsy not typically required for a first episode in a child with typical features).

Treatment: high-dose prednisolone induces complete remission in 85 to 95% of children and 75 to 85% of adults within 4 to 8 weeks. Relapses are common (50 to 75% of children) — treated with repeat steroid courses or, for frequent relapsers and steroid-dependent cases, calcineurin inhibitors (tacrolimus, cyclosporine) or mycophenolate to reduce steroid exposure. Rituximab for refractory or frequently relapsing MCD. At KIMS, MCD is managed with the standard ISKDC protocol and monitored with urine ACR.

Multiple myeloma is a plasma cell malignancy producing massive quantities of abnormal immunoglobulin light chains that damage the kidneys through multiple mechanisms: cast nephropathy (the most common — light chains bind Tamm-Horsfall protein in the distal tubule, forming obstructing casts and causing AKI, often the presenting manifestation of myeloma), light chain deposition disease (LCDD — granular deposits in the GBM and TBM), and AL amyloidosis (amyloid fibrils causing nephrotic syndrome). Hypercalcaemia from bony myeloma adds further nephrotoxicity.

The most important clinical message: myeloma kidney is a medical emergency — rapid reduction of the serum light chain burden by bortezomib-based chemotherapy (which reduces free light chains within days to weeks) is the definitive treatment. CRRT supports the patient through AKI while chemotherapy takes effect. Kidney function improves in approximately 50% of cast nephropathy patients who achieve a haematological response. At KIMS, the nephrology and haematology-oncology teams manage myeloma kidney jointly, with kidney biopsy distinguishing cast nephropathy from LCDD and AL amyloidosis.

Nephrocalcinosis is calcium deposition within the renal parenchyma -- visible on ultrasound (echogenic medullary pyramids), plain X-ray (medullary calcifications), or CT. It is distinct from nephrolithiasis (stones within the collecting system) -- the calcium in nephrocalcinosis is deposited within the kidney tissue itself, directly damaging tubular cells. The most common causes of medullary nephrocalcinosis: Type 1 distal renal tubular acidosis (RTA -- the most important treatable cause), primary hyperparathyroidism (hypercalcaemia), medullary sponge kidney, hyperoxaluria, and hypervitaminosis D.

Investigation: serum calcium, PTH, 25-OH vitamin D, ACE level (sarcoidosis), 24-hour urine calcium and oxalate, urine anion gap (for Type 1 RTA). Treatment of the underlying cause halts further calcium deposition -- potassium citrate for Type 1 RTA, parathyroidectomy for primary hyperparathyroidism, stopping vitamin D supplementation for hypervitaminosis D. Established calcium deposits do not dissolve with treatment -- stabilisation is the goal. At KIMS, all nephrocalcinosis is evaluated through the metabolic stone clinic.

Nephrotic syndrome is defined by heavy proteinuria (above 3.5 g/day), hypoalbuminaemia (serum albumin below 25 g/L), and generalised oedema. The frothy urine of heavy proteinuria is often the first symptom. Complications include severe oedema, deep vein thrombosis and pulmonary embolism (from loss of natural anticoagulants in the urine), infections (from immunoglobulin loss), and hyperlipidaemia.

Important causes in India by age: children -- minimal change disease (85%); adults -- membranous nephropathy, FSGS, diabetic nephropathy, amyloidosis, and lupus nephritis Class V. Kidney biopsy is required in adults to guide immunosuppression. At KIMS, the complete nephrotic evaluation includes 24-hour urine protein, serum albumin, lipid profile, coagulation screen, ANA, anti-dsDNA, complement, and anti-PLA2R for membranous nephropathy.

Nocturia -- waking from sleep one or more times to void -- affects approximately 50% of adults above 60 and is a major determinant of sleep quality and daytime fatigue. The underlying causes: nocturnal polyuria (excess urine production at night -- from evening fluid overload, salt intake, or impaired ADH secretion in the elderly), reduced bladder capacity (from BPH, OAB, bladder fibrosis, IC/BPS), or both.

Bladder diary (3 to 7 days) is the most diagnostically useful tool -- distinguishing nocturnal polyuria from reduced bladder capacity. Management: evening fluid restriction, reduced evening salt and alcohol intake, desmopressin for nocturnal polyuria (with sodium monitoring), anticholinergics or mirabegron for OAB-related nocturia, alpha-blockers or HoLEP for BPH-related nocturia. At KIMS, nocturia is evaluated with the bladder diary before any treatment is prescribed.

Overactive bladder (OAB) is defined by urinary urgency with or without urgency incontinence, usually accompanied by frequency (8 or more voidings per day) and nocturia, in the absence of UTI or other identifiable pathology. It affects approximately 12% of adults and significantly impairs quality of life. OAB results from involuntary detrusor contractions during the bladder filling phase.

Bladder diary confirms the frequency-urgency pattern. First-line: bladder training and pelvic floor muscle training. Second-line: antimuscarinic medications (oxybutynin, solifenacin) or beta-3 agonist (mirabegron -- preferred in elderly patients for fewer anticholinergic side effects). Third-line for refractory OAB: intravesical botulinum toxin A injection or sacral neuromodulation. At KIMS, urodynamics distinguishes OAB from stress incontinence and bladder outlet obstruction before treatment.

Renal papillary necrosis is ischaemic death of the renal papillae -- caused by conditions reducing medullary blood flow. In India, the most common causes are diabetes mellitus (especially with acute pyelonephritis), long-term NSAID use (analgesic nephropathy), sickle cell disease, and genitourinary tuberculosis. The necrotic papilla may remain in situ or slough into the collecting system -- causing haematuria and ureteric obstruction mimicking stone colic.

A sloughed papilla on CT appears as a soft tissue density filling defect in the ureter -- not calcium-dense like a stone. Treatment: remove the underlying cause (stop NSAIDs, optimise glycaemic control, treat TB), manage haematuria with hydration or selective renal artery embolisation for massive haematuria, relieve ureteric obstruction by ureteroscopy or JJ stenting.

Peyronie's disease is the development of fibrous scar plaques within the tunica albuginea of the penis -- causing penile curvature during erection, pain, shortening, and erectile dysfunction. It affects approximately 3 to 9% of adult men. The scar forms at sites of repetitive microtrauma during sexual intercourse, in men with a predisposition to abnormal fibrotic healing (associated with HLA-B7 and Dupuytren's contracture). Peyronie's has an active phase (pain, progressive curvature -- 6 to 18 months) and a stable phase (curvature fixed, pain typically resolved).

Treatment: active phase -- oral pentoxyfilline, vitamin E, and traction devices. Stable phase (curvature not changed for at least 3 months): collagenase clostridium histolyticum (Xiaflex) injection -- the only pharmacological treatment with RCT evidence. Surgery for significant stable curvature: Nesbit plication, plaque incision with grafting, or penile prosthesis for combined Peyronie's disease and severe erectile dysfunction. At KIMS, surgery is only performed after curvature has been stable for at least 3 months.

Pheochromocytoma is a catecholamine-secreting adrenal tumour causing the classic paroxysmal triad of headache, sweating, and palpitations with hypertension that may be episodic or sustained. It is present in approximately 0.1 to 0.6% of hypertensive patients. Operating without adequate alpha-blockade causes fatal intraoperative hypertensive crisis -- the most dangerous consequence of missing this diagnosis.

Biochemical diagnosis: plasma metanephrines (sensitivity above 97%) or 24-hour urine catecholamines and metanephrines. CT or MRI for localisation. Genetic testing for SDHB, VHL, RET, NF1 mutations in all patients. Mandatory pre-operative preparation: alpha-blockade with phenoxybenzamine or doxazosin for 10 to 14 days before surgery. Robotic adrenalectomy at KIMS with specific intraoperative catecholamine surge management protocol.

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease -- affecting 1 in 400 to 1 in 1,000 people. Caused by mutations in PKD1 (85%) or PKD2 (15%), ADPKD causes progressive bilateral cyst enlargement, massive kidney enlargement, and ESRD by age 50 to 70 (PKD1) or 70 to 80 (PKD2). Associated features: hepatic cysts (80%), intracranial aneurysms (8 to 12% -- requiring MRA screening), hypertension from the 2nd to 3rd decade.

Tolvaptan -- the only disease-modifying therapy, slowing total kidney volume growth and eGFR decline in rapidly progressive ADPKD. ACE inhibitors for blood pressure. At KIMS, ADPKD patients undergo genetic counselling, total kidney volume measurement (for tolvaptan eligibility), MRA for intracranial aneurysm screening, and family cascade screening.

Post-infectious glomerulonephritis -- most commonly post-streptococcal GN -- develops 1 to 3 weeks after streptococcal throat infection or 3 to 6 weeks after skin infection (impetigo). It presents with the nephritic syndrome: cola-coloured urine (haematuria with red cell casts), periorbital oedema, hypertension, and oliguria. Low serum C3 (with normal C4) is characteristic.

PIGN is almost always self-limiting in children -- 95 to 100% recover completely with supportive management. Persistent haematuria beyond 12 months, persistent low C3 beyond 8 to 12 weeks, or atypical features should prompt kidney biopsy to exclude IgA nephropathy, C3 glomerulopathy, or lupus nephritis. Adult PIGN has a less favourable prognosis -- 25 to 30% develop persistent CKD.

Premature ejaculation (PE) is the most common male sexual dysfunction, affecting 20 to 30% of men across all age groups. Lifelong PE has a neurobiological basis and responds well to pharmacological treatment. Acquired PE is more often associated with erectile dysfunction, prostatitis, thyroid dysfunction, or psychological factors.

Pharmacological treatment: dapoxetine (the only on-demand licensed drug -- taken 1 to 3 hours before sexual activity, increases ejaculatory latency 2 to 3 fold) or daily SSRIs (paroxetine -- the most effective by meta-analysis). Topical anaesthetics (lidocaine-prilocaine cream) reduce penile sensitivity. Behavioural therapy (stop-start technique) for psychological and acquired PE. At KIMS, PE is assessed in the andrology programme with a confidential consultation.

Prostate cancer is the second most common cancer in men globally, with rising incidence in urban India. PSA is the primary screening test -- but PSA elevation is not specific to cancer (BPH and prostatitis also raise PSA). Diagnosis: multi-parametric MRI (mpMRI) followed by MRI-fusion targeted biopsy, which significantly improves cancer detection and reduces unnecessary biopsies.

Treatment depends on risk stratification: active surveillance for low-risk disease, robotic radical prostatectomy (RARP using Da Vinci Xi at KIMS) or radiation for intermediate and high-risk localised cancer, androgen deprivation therapy (ADT) for locally advanced and metastatic disease, combined with docetaxel or abiraterone for metastatic disease. At KIMS, all prostate cancer cases are reviewed at the MDT tumour board.

Prostatitis encompasses four NIH categories: acute bacterial (Category I -- fever, perineal pain, obstructive symptoms, positive urine culture -- requires 4 to 6 weeks of quinolone antibiotics), chronic bacterial (Category II -- recurrent UTIs from same organism), chronic pelvic pain syndrome (Category III -- the most common, 90% of cases -- perineal or pelvic pain above 3 months without infection), and asymptomatic inflammatory (Category IV).

Category III (CPPS) is challenging to treat -- alpha-blockers (tamsulosin), anti-inflammatories, phytotherapy (quercetin), physiotherapy, and cognitive behavioural therapy all have evidence for symptom improvement. PSA may be elevated in all prostatitis categories -- biopsy should be deferred until 4 to 6 weeks after treatment. At KIMS, CPPS is managed in the urology and andrology clinic.

Proteinuria -- abnormal quantities of protein in the urine -- is the most important marker of kidney disease. Quantification: urine albumin-to-creatinine ratio (ACR) from a spot specimen. Normal: below 3 mg/mmol. Moderately increased (microalbuminuria): 3 to 30 mg/mmol. Severely increased (macroalbuminuria): above 30 mg/mmol. Heavy proteinuria above 350 mg/mmol warrants kidney biopsy.

ACE inhibitors and ARBs reduce proteinuria and slow CKD progression in all proteinuric kidney diseases. SGLT2 inhibitors further reduce proteinuria and CKD progression, with a 30 to 40% reduction in the composite kidney endpoint in the CREDENCE and DAPA-CKD trials. At KIMS, urine ACR is the fundamental test for detecting and monitoring kidney disease in every patient with diabetes, hypertension, or suspected glomerular disease.

Pyonephrosis is pus within an obstructed renal collecting system -- a urological emergency combining infection and obstruction. The obstructed kidney cannot drain infected urine, and antibiotics cannot achieve effective concentrations within the infected system -- without drainage, the patient develops rapid septicaemia, septic shock, and permanent kidney destruction. Most common cause in India: calculus disease with secondary infection.

Emergency management: drainage first -- either percutaneous nephrostomy (PCN) under ultrasound guidance or retrograde JJ stent insertion -- combined with broad-spectrum IV antibiotics. Drainage always takes precedence over stone surgery. Renal ultrasound confirms the diagnosis (hydronephrosis with internal echoes in the collecting system). CT identifies the level and cause of obstruction. At KIMS, PCN insertion is available 24/7 for pyonephrosis.

Renal amyloidosis is deposition of misfolded protein fibrils (amyloid) in the kidney -- causing progressive nephrotic syndrome and CKD. The two most important types: AL amyloidosis (from plasma cell dyscrasia -- light chains misfold into amyloid fibrils, the same mechanism as in MGRS and myeloma) and AA amyloidosis (from chronic inflammation -- rheumatoid arthritis, inflammatory bowel disease, chronic infections, tuberculosis -- where serum amyloid A protein forms the fibril precursor). Diagnosis requires kidney biopsy: Congo red positive staining with apple-green birefringence under polarised light, and 8 to 12nm amyloid fibrils on electron microscopy.

AL amyloidosis is treated with bortezomib-based or daratumumab-based chemotherapy targeting the plasma cell clone -- reducing light chain production and halting further amyloid deposition. AA amyloidosis is treated by controlling the underlying inflammatory disease. Organ recovery occurs slowly over 6 to 18 months of sustained haematological response. Cardiac amyloidosis (restrictive cardiomyopathy) is the dominant determinant of prognosis and is managed by the cardiology team. At KIMS, amyloidosis is managed jointly by nephrology and haematology-oncology.

Renal artery stenosis (RAS) is narrowing of one or both renal arteries -- causing renovascular hypertension (driven by RAAS activation from the ischaemic kidney) and ischaemic nephropathy (progressive loss of kidney function from inadequate renal perfusion). The two main causes: atherosclerotic RAS (90% of cases -- in patients above 55 with cardiovascular risk factors, typically affecting the ostium of the renal artery) and fibromuscular dysplasia (FMD -- in young women, affecting the mid or distal renal artery with the characteristic beads-on-a-string appearance).

Suspect RAS when: hypertension resistant to three or more antihypertensives, creatinine rises more than 30% when ACE inhibitors or ARBs are started, flash pulmonary oedema without cardiac cause, or hypertension onset before age 30 (suggesting FMD). Diagnosis: renal Doppler, CT angiography, or MR angiography. FMD responds excellently to angioplasty -- blood pressure cure in 50 to 80% of young women. Atherosclerotic RAS: angioplasty and stenting reserved for haemodynamically significant lesions with deteriorating kidney function or flash pulmonary oedema.

Renal osteodystrophy is the bone disease of CKD -- part of the broader syndrome of CKD-Mineral and Bone Disorder (CKD-MBD). As eGFR declines, phosphate accumulates (the kidneys cannot excrete it), vitamin D activation is impaired (1-alpha hydroxylase in the kidney converts 25-OH vitamin D to active calcitriol), and PTH rises compensatorily (secondary hyperparathyroidism). These hormonal changes cause high-turnover bone disease (osteitis fibrosa cystica -- from excess PTH stimulating osteoclasts), low-turnover bone disease (adynamic bone -- from over-suppression of PTH), and vascular calcification.

Treatment: phosphate restriction and phosphate binders (calcium carbonate, sevelamer -- taken with meals to bind dietary phosphate), activated vitamin D supplements (alfacalcidol or calcitriol -- to suppress secondary hyperparathyroidism), cinacalcet (calcimimetic -- suppresses PTH without raising calcium), and parathyroidectomy for refractory secondary hyperparathyroidism above 800 pg/ml despite medical therapy. Annual CKD-MBD blood panel at KIMS: calcium, phosphate, intact PTH, alkaline phosphatase, and 25-OH vitamin D.

Renal tubular acidosis is a group of disorders in which the kidney's tubular system fails to properly acidify the urine -- despite normal or near-normal GFR. Type 1 (distal RTA): failure to secrete H+ in the collecting duct -- causes normal anion gap metabolic acidosis, hypokalaemia, hypercalciuria, hypocitraturia, and alkaline urine -- the classic metabolic cause of recurrent calcium phosphate kidney stones and nephrocalcinosis. Type 2 (proximal RTA): failure to reabsorb bicarbonate -- causes Fanconi syndrome (glycosuria, aminoaciduria, phosphaturia). Type 4 RTA: aldosterone deficiency or resistance -- the most common type, causing hyperchloraemic acidosis with hyperkalaemia in diabetic nephropathy.

The most clinically impactful diagnosis in the stone clinic: Type 1 RTA causes recurrent calcium phosphate stones that stop completely with potassium citrate -- a cheap, safe, oral treatment that simultaneously corrects the acidosis, raises urinary citrate, and normalises urinary pH. Potassium citrate is one of the most satisfying treatments in nephrology for this reason -- a patient with 5 or 6 stone procedures over 10 years may simply need the correct metabolic diagnosis.

Renovascular disease encompasses a spectrum of disorders affecting the blood vessels of the kidney -- from renal artery stenosis and occlusion (large vessel), to renal vein thrombosis (venous), to thrombotic microangiopathy and atheroembolic disease (small vessel). Each produces a different clinical picture. Renal vein thrombosis is an important complication of nephrotic syndrome -- the loss of natural anticoagulants in the urine creates a profoundly prothrombotic state, and membranous nephropathy has the highest thrombotic risk among nephrotic causes.

Renal infarction (from renal artery occlusion) presents with sudden severe loin pain, elevated LDH, and rising creatinine -- diagnosed by CT with contrast showing the wedge-shaped perfusion defect. Cholesterol crystal embolism (atheroembolic renal disease) occurs after aortic catheterisation or spontaneous plaque rupture -- livedo reticularis, digital ischaemia, eosinophilia, and renal failure are the clinical clues. At KIMS, all forms of renovascular disease are investigated and managed by the nephrology and vascular teams.

Retroperitoneal fibrosis (RPF) is fibrotic tissue proliferating in the retroperitoneum -- surrounding and compressing the aorta, inferior vena cava, and ureters, causing progressive ureteric obstruction, hydronephrosis, and AKI or CKD. Two-thirds of cases are idiopathic -- and a significant proportion of these are now recognised as IgG4-related disease (elevated serum IgG4, IgG4-positive plasma cell infiltration on biopsy). Secondary causes include malignancy (the most important to exclude before steroids), prior aortic surgery, and inflammatory AAA.

CT shows the periaortic fibrotic mass with medial deviation of the ureters (pathognomonic). Biopsy excludes malignancy and confirms IgG4 involvement. Treatment: urgent ureteric stenting for decompression, then prednisolone (which dramatically shrinks IgG4-related RPF within weeks). Surgical ureterolysis for steroid-refractory cases. TB must be excluded before starting steroids in India -- both TB lymphadenopathy and RPF can cause periaortic fibrosis with ureteric obstruction.

Rhabdomyolysis is rapid breakdown of skeletal muscle -- releasing myoglobin, potassium, phosphate, and creatine kinase into the bloodstream. Myoglobin precipitates in renal tubules at high concentrations, causing tubular obstruction and AKI. The classic presentation: dark brown or cola-coloured urine (myoglobinuria), severe muscle pain and weakness, and rising creatinine. Causes in India: road traffic accident crush injuries (most common), extreme exercise in untrained individuals, seizures, alcohol excess, statin toxicity, infections (including leptospirosis -- an important Indian cause), and heat stroke.

Treatment: the most time-sensitive intervention is massive IV fluid resuscitation -- targeting urine output above 200 to 300 ml/hour to dilute and flush myoglobin through the tubules before precipitation. Volumes of 10 to 20 litres in 24 hours are required in severe cases. Electrolyte management: treat hyperkalaemia (the most dangerous electrolyte complication) with calcium gluconate, insulin-dextrose, and bicarbonate. CRRT for severe AKI at KIMS. Compartment syndrome: emergency fasciotomy. Most AKI from rhabdomyolysis recovers completely with aggressive early hydration.

Scleroderma renal crisis (SRC) is a potentially fatal complication of systemic sclerosis (SSc) -- occurring in 5 to 10% of SSc patients, characterised by sudden onset severe hypertension, rapidly rising creatinine (AKI), and features of thrombotic microangiopathy (haemolytic anaemia, thrombocytopenia) in approximately 50% of cases. The mechanism: SSc-related renal artery intimal proliferation causes critical reduction in renal blood flow -- triggering massive renin release, RAAS activation, and a catastrophic positive feedback cycle of hypertension and ischaemia.

ACE inhibitors (captopril -- the preferred agent for its short half-life allowing rapid titration) are the life-saving treatment -- they break the renin-angiotensin cycle. Target BP below 120/80 within 72 hours of SRC onset. Withholding ACE inhibitors because of 'AKI risk' is a fatal error -- they are the treatment. High-dose steroids above 15mg prednisolone can trigger SRC in SSc patients and must be used cautiously. Some SRC patients on dialysis recover kidney function 3 to 18 months later if ACE inhibitors are continued throughout. At KIMS, SRC is managed in the women's nephrology programme.

Sickle cell nephropathy describes the spectrum of kidney disease in sickle cell disease (HbSS) -- from early, universal hyposthenuria (inability to concentrate urine, from destruction of the medullary countercurrent system) to haematuria (from medullary infarction and papillary necrosis), proteinuria, and CKD (affecting 20 to 30% of HbSS patients) to ESRD (4 to 18%). The renal medulla is particularly vulnerable because its hypoxic, hyperosmolar environment promotes HbS polymerisation and sickling in the vasa recta. In Telangana and Andhra Pradesh, sickle cell disease is prevalent in tribal and rural populations.

Management: ACE inhibitors started at microalbuminuria (ACR above 3 mg/mmol) -- the most important kidney-protective intervention; hydroxyurea (reduces sickling, reduces albuminuria, and slows eGFR decline); blood pressure control; avoidance of nephrotoxins (NSAIDs, contrast dye); adequate hydration at all times. Haematuria from medullary sickling: vigorous IV hydration and urinary alkalinisation -- selective renal artery embolisation for massive haematuria. Transplant for ESRD -- with continued hydroxyurea post-transplant. At KIMS, sickle cell nephropathy is managed through the nephrology programme.

A spermatocele is a benign cyst arising from the epididymis -- found in 20 to 40% of adult men on scrotal ultrasound. It contains serous fluid with dead sperm cells, giving it a milky appearance. A spermatocele is soft, fluctuant, transilluminates (unlike a solid tumour), and is clearly separate from the testis -- above and behind it. The most important clinical distinction: spermatocele is distinct from testicular cancer, which arises within the testicle itself and is firm, non-transilluminating. All scrotal lumps should be confirmed by scrotal ultrasound to make this distinction with certainty.

The vast majority of spermatoceles require no treatment -- they are benign, do not affect fertility, and do not become malignant. Spermatocelectomy (surgical removal) is considered only for significantly symptomatic spermatoceles (persistent pain or very large size causing scrotal heaviness). Aspiration alone has near-universal recurrence. Important fertility counselling for men of reproductive age: spermatocelectomy risks disruption of the epididymal tubules, causing obstructive azoospermia in the operated testicle -- a risk that typically outweighs the benefit of surgery for a benign condition.

Stress urinary incontinence (SUI) -- leakage of urine with coughing, sneezing, laughing, lifting, or exercise -- is the most common type of urinary incontinence in women, affecting 30 to 40% of women who have had vaginal deliveries and increasing in prevalence after menopause. It is caused by inadequate urethral sphincter support (from weakened pubourethral ligaments and endopelvic fascia) -- not by a bladder contraction (which distinguishes it from OAB). No woman needs to accept SUI as an inevitable consequence of ageing or childbirth -- effective treatments exist at every severity level.

First-line: supervised pelvic floor muscle training (PFMT) with a physiotherapist -- achieves 50 to 70% improvement or cure in mild to moderate SUI. Second-line: mid-urethral sling surgery (TVT or TOT -- minimally invasive day-case procedure at KIMS) achieving 80 to 90% cure for moderate to severe SUI. Weight loss reduces SUI significantly (PRIDE trial: 8% weight loss reduces incontinence episodes by 47%). Topical oestrogen for postmenopausal women. Pre-operative urodynamics identifies occult stress incontinence in women with large cystocele before prolapse repair.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by autoantibodies (particularly ANA and anti-dsDNA) causing inflammation in multiple organ systems -- the joints, skin, kidneys, brain, lungs, and heart. Kidney involvement (lupus nephritis) occurs in 40 to 70% of SLE patients and is the most important determinant of long-term prognosis. Lupus nephritis is classified into six ISN/RPS classes by kidney biopsy findings -- from minimal mesangial disease (Class I) to diffuse proliferative GN (Class IV) to membranous LN (Class V). The 'full house' immunofluorescence pattern (IgG + IgA + IgM + C3 + C4 + C1q) is pathognomonic.

All patients with confirmed lupus nephritis are treated with hydroxychloroquine (the background anti-SLE drug) plus class-specific immunosuppression. Class III/IV: mycophenolate + prednisolone (or cyclophosphamide + prednisolone for severe disease). Voclosporin added to mycophenolate achieves higher complete remission rates. Belimumab reduces flares. At KIMS, all SLE patients with proteinuria or declining eGFR are evaluated by the women's nephrology programme for lupus nephritis.

Testicular cancer is the most common solid malignancy in men aged 15 to 35 -- though overall incidence remains lower in India than in Western populations. The two main types: seminoma (pure germ cell tumour -- occurring in slightly older men, 30s to 40s -- highly radiosensitive and chemosensitive, excellent prognosis) and non-seminomatous germ cell tumour (NSGCT -- embryonal carcinoma, teratoma, yolk sac tumour, choriocarcinoma -- occurring in men in their 20s to 30s -- treated with BEP chemotherapy or surveillance for Stage I). Tumour markers: AFP (alpha-fetoprotein -- elevated in NSGCT), hCG (elevated in choriocarcinoma and some NSGCT), and LDH.

The cardinal symptom is a painless hard lump within the testicle -- scrotal ultrasound confirms the testicular origin. Serum tumour markers (AFP, hCG, LDH) and CT chest-abdomen-pelvis for staging before orchidectomy. Radical orchidectomy (through an inguinal incision -- not scrotal, to avoid disrupting the lymphatic drainage) is the definitive diagnosis and first treatment. Surveillance for low-stage I disease, BEP chemotherapy for Stage II and III. Testicular cancer has one of the highest cure rates of any solid malignancy -- above 95% overall. At KIMS, all testicular masses are evaluated urgently by the uro-oncology team.

Testicular torsion is rotation of the testicle on its spermatic cord -- twisting the blood vessels and causing ischaemia. It is the most important acute scrotal emergency, requiring surgical exploration within 4 to 6 hours of onset to save the testicle. Beyond 6 hours the salvage rate falls rapidly -- from above 90% within 6 hours to below 10% after 24 hours. It occurs most commonly in adolescent boys (peak 12 to 18 years) and occasionally in neonates, but can occur at any age. It is not caused by trauma -- it usually occurs at rest or during sleep, from the 'bell clapper deformity' (a high attachment of the tunica vaginalis that allows the testicle to rotate freely).

The classic presentation: sudden, severe testicular pain (often waking from sleep), scrotal swelling and erythema, nausea and vomiting, high-riding tender testicle. Absent or reduced blood flow on scrotal Doppler ultrasound confirms the diagnosis -- but if clinical suspicion is high, surgical exploration must not be delayed for imaging. Treatment: immediate surgical exploration -- if torsion is confirmed, the testicle is untwisted and fixed (orchidopexy) if viable, or removed if infarcted. The contralateral testicle is always fixed simultaneously (bilateral orchidopexy) because the anatomical predisposition is bilateral. At KIMS, emergency scrotal exploration for suspected torsion is available 24/7.

Thrombotic microangiopathy (TMA) is a clinical syndrome of microangiopathic haemolytic anaemia (red cell fragmentation -- schistocytes on blood film), thrombocytopenia, and end-organ ischaemia from small vessel platelet-fibrin thrombi -- most commonly affecting the kidneys (AKI) and brain. The three main causes require completely different treatments: TTP (ADAMTS13 deficiency -- treat with plasma exchange), STEC-HUS (Shiga toxin E. coli -- manage supportively, NO antibiotics or anti-motility agents), and aHUS (complement dysregulation -- treat with eculizumab).

The peripheral blood film showing schistocytes (fragmented red cells) is the essential bedside diagnostic tool triggering the TMA workup. Plasma exchange must be started immediately in any TMA where TTP cannot be excluded -- waiting for ADAMTS13 results before starting exchange is dangerous. Platelet transfusion is avoided in TMA (adds substrate for further microvascular thrombosis). At KIMS, TMA is a medical emergency with 24/7 availability of plasma exchange, ADAMTS13 testing, complement studies, and CRRT.

Tumor lysis syndrome is a life-threatening metabolic emergency occurring when massive cancer cell destruction -- from chemotherapy, radiation, or spontaneously in highly proliferative tumours -- releases potassium, phosphate, and nucleic acids (converted to uric acid) simultaneously into the bloodstream. The resulting metabolic storm: hyperuricaemia (uric acid precipitates in renal tubules -- causing AKI), hyperkalaemia (cardiac arrhythmia risk), hyperphosphataemia, and hypocalcaemia (from phosphate-calcium binding -- causing tetany and arrhythmias). Highest risk: Burkitt lymphoma (the highest proliferative rate), ALL with high WBC, DLBCL.

Prevention: IV hydration at 2 to 3 litres/m squared per day starting 24 to 48 hours before chemotherapy, allopurinol (for intermediate risk -- prevents new uric acid synthesis), rasburicase (for high risk -- rapidly converts existing uric acid to soluble allantoin within 4 to 24 hours; contraindicated in G6PD deficiency). Treatment when TLS occurs: continue IV hydration, correct hyperkalaemia (calcium gluconate, insulin-dextrose), give rasburicase for severe hyperuricaemia, and initiate CRRT for severe AKI or refractory electrolyte abnormalities. At KIMS, TLS prophylaxis and management is a joint nephrology-oncology responsibility.

Cryptorchidism (undescended testicle) is the most common congenital genital abnormality in male infants -- occurring in 2 to 4% of full-term male births. The testicle fails to complete its normal descent from the abdomen through the inguinal canal into the scrotum. If not corrected, the higher-than-normal temperature damages spermatogenic cells progressively from 6 months of age -- causing reduced fertility -- and increases the lifetime risk of testicular cancer (approximately 10 times the general population risk in the affected testicle).

Spontaneous descent occurs in 70% of undescended testicles by 3 to 6 months of age. Orchidopexy (bringing the testicle into the scrotum surgically) performed between 6 and 18 months of age gives the best fertility outcomes. After puberty, orchidopexy does not improve spermatogenesis but allows surveillance of the at-risk testicle. At KIMS, inguinal orchidopexy and laparoscopic orchidopexy for non-palpable undescended testicles are performed as day-case procedures by Dr. Neil Narendra Trivedi.

Upper tract urothelial carcinoma (UTUC) is cancer arising from the urothelium lining the renal pelvis or ureter -- accounting for 5 to 10% of all urothelial cancers. Risk factors include smoking, aristolochic acid (from Chinese herbal medicines), Lynch syndrome (MMR gene mutations -- MSH2 carriers have up to 25% lifetime UTUC risk), and prior bladder cancer (patients with UTUC have a 15 to 50% lifetime risk of developing bladder cancer -- the entire urothelium shares the carcinogenic exposure). Painless haematuria is the cardinal symptom.

The critical diagnostic gap: cystoscopy examines only the bladder -- a normal cystoscopy does not exclude UTUC. CT urogram (with excretory phase imaging) is required to visualise the upper tract and detect the filling defects caused by UTUC. Radical nephroureterectomy (RNU -- removal of the kidney, entire ureter, and bladder cuff) is the gold standard treatment, performed robotically using the Da Vinci Xi at KIMS. Lifelong cystoscopy surveillance is mandatory after RNU because of the 20 to 50% bladder recurrence risk.

Uremia (uraemia) is the clinical syndrome caused by accumulation of metabolic waste products -- urea, creatinine, uraemic organic acids, middle molecules, and protein-bound toxins -- when the kidneys fail to excrete them adequately. Symptoms are multisystem: fatigue and profound weakness (universal), nausea and vomiting (particularly in the morning), anorexia, cognitive fog, peripheral neuropathy (restless legs, burning paraesthesias), uraemic pruritus (intractable itch -- not relieved by antihistamines), uraemic pericarditis (chest pain worsened lying flat -- an emergency indication for dialysis), and in severe untreated uremia -- encephalopathy, seizures, and coma.

Uremia signals the need for kidney replacement therapy -- dialysis or transplant. Emergency indications for immediate dialysis: uraemic pericarditis, encephalopathy, refractory hyperkalaemia (above 6.5 mEq/L with ECG changes), severe metabolic acidosis (pH below 7.1), or pulmonary oedema from fluid overload. The best time to start transplant evaluation is when eGFR falls below 20 ml/min -- before dialysis ever begins. Pre-emptive transplant (before dialysis) provides the best long-term outcomes. At KIMS, 1,500+ transplants performed with NOTTO registration and TSTA empanelment.

Urinary diversion is the surgical rerouting of urine from the kidneys when the bladder has been removed (radical cystectomy) or is non-functional. The three options: ileal conduit (urostomy bag -- simplest, most reliable), orthotopic neobladder (reservoir anastomosed to the urethra -- the patient voids by abdominal straining, no external bag, but nocturnal incontinence in 20 to 50%), and continent cutaneous reservoir (Indiana pouch -- the patient self-catheterises an abdominal stoma every 4 to 6 hours, no external bag).

The choice of diversion must be made before surgery -- after the bladder is removed, the options are fixed. At KIMS, every radical cystectomy patient has a pre-operative counselling session with the urology team and a stoma nurse. Robotic radical cystectomy (RARC) using the Da Vinci Xi is performed by Dr. K. V. R. Prasad. Annual monitoring after diversion: creatinine, eGFR, urine culture, B12 level (ileal segments impair B12 absorption), and upper tract ultrasound for ureteric stricture.

Urinary tract infections are among the most common bacterial infections in India -- affecting 50 to 60% of women at least once in their lifetime. Cystitis (lower UTI -- dysuria, frequency, urgency, suprapubic pain) is the most common form. Pyelonephritis (upper UTI -- fever above 38 degrees C, loin pain, rigors) is more severe and requires 10 to 14 days of antibiotics (ciprofloxacin or co-amoxiclav). Recurrent UTI (3 or more episodes per year) affects 25% of women with a history of UTI and requires investigation for structural abnormalities, metabolic predispositions, and -- in men and children -- underlying urological causes.

E. coli causes 70 to 80% of uncomplicated UTIs. Extended-spectrum beta-lactamase (ESBL) E. coli is increasingly prevalent in India from antibiotic overuse -- requiring nitrofurantoin (for lower UTI), or carbapenems for systemic infection. Antibiotic prophylaxis (low-dose trimethoprim or nitrofurantoin) for recurrent UTI reduces frequency by 90%. At KIMS, recurrent UTIs are systematically investigated with urine culture, renal ultrasound, post-void residual, and cystoscopy where indicated.

Urinary tract obstruction (UTO) is any condition impeding normal urine flow from kidney to bladder -- causing hydronephrosis (dilation of the collecting system) and, if bilateral or prolonged, AKI or progressive CKD. Common causes: ureteric stones (the most common cause of acute unilateral obstruction), BPH (the most common cause of chronic bladder outlet obstruction in men above 50 -- causing bilateral hydronephrosis), tumour (extrinsic compression of the ureter), stricture (ureteric or urethral), and PUV (in male infants).

Bilateral complete obstruction is a urological emergency -- immediate drainage (catheterisation for bladder outlet obstruction, JJ stenting or PCN for ureteric obstruction) restores kidney function if performed promptly. Post-obstructive diuresis after relief of chronic bilateral obstruction can cause life-threatening fluid and electrolyte losses -- requiring IV fluid replacement of 50 to 75% of urine output with hourly monitoring. At KIMS, 24/7 emergency urology is available for acute urinary retention and pyonephrosis.

UPJ obstruction is a blockage at the junction between the renal pelvis and the ureter -- causing hydronephrosis, impaired drainage, and kidney function loss. It may be congenital (the most common cause -- detected antenatally or in childhood) or acquired (from a crossing lower pole vessel, kidney stone, or scar tissue). The Dietl crisis -- sudden severe loin pain precipitated by large fluid intake -- is the classic symptomatic presentation in adults, as increased urine production overwhelms the narrowed UPJ.

Functional significance is assessed by DTPA renogram with diuretic -- measuring differential kidney function and drainage half-time. Surgery is indicated when differential function falls below 40% or declines on serial renograms. Robotic pyeloplasty (Anderson-Hynes dismembered pyeloplasty using the Da Vinci Xi or X at KIMS) achieves above 90 to 95% long-term success with a 1 to 2 night hospital stay -- the gold standard repair, performed by Dr. Likhiteswer Pallagani.

Urethral stricture -- scar tissue narrowing the urethra -- causes progressive obstructive urinary symptoms: reduced stream, hesitancy, spraying, incomplete emptying, recurrent UTIs, and eventually acute urinary retention. Common causes in India: gonococcal urethritis (untreated gonorrhoea causing dense pan-urethral stricture), pelvic fracture urethral injury (PFUI -- posterior urethral disruption), iatrogenic (post-catheterisation, post-TURP, post-radical prostatectomy anastomotic stricture), and lichen sclerosus (BXO -- causing meatal and anterior urethral stricture).

Repeated urethral dilatation is not a cure and is actively harmful -- each dilatation creates new scar tissue, progressively worsening the stricture. Optical internal urethrotomy (OIU) is appropriate for short first-presentation bulbar strictures. For longer or recurrent strictures, urethroplasty is the definitive treatment: anastomotic urethroplasty (excision and primary anastomosis -- above 90% success at 5 years for short strictures) or buccal mucosa urethroplasty (hairless, wet tissue ideal for urethral reconstruction -- above 80 to 85% success for long strictures). At KIMS, Dr. K. V. R. Prasad performs the full range of urethroplasty procedures.

A varicocele is an abnormal dilation of the pampiniform venous plexus within the spermatic cord -- the male equivalent of varicose veins, occurring predominantly on the left side (90% of cases -- from the perpendicular entry of the left testicular vein into the left renal vein, creating a column of venous pressure). Varicoceles are found in 15% of the general male population and in 35 to 40% of men presenting with primary infertility -- making it the most common surgically correctable cause of male infertility. The mechanism of infertility: elevated scrotal temperature from impaired venous drainage reduces spermatogenesis.

Diagnosis: clinical examination (a bag-of-worms feel in the standing patient, accentuated by Valsalva manoeuvre), confirmed by scrotal Doppler ultrasound (venous diameter above 3mm, reversed flow on Valsalva). Treatment indication: clinical varicocele (Grade 2 to 3) + abnormal semen analysis + couple attempting pregnancy. Microsurgical subinguinal varicocelectomy is the gold standard -- preserving the testicular artery and lymphatics while ligating all dilated veins, improving sperm parameters in 60 to 70% of patients and achieving spontaneous pregnancy in 30 to 50%. At KIMS, varicocelectomy is performed as a day-case under general or spinal anaesthesia.

Vesicoureteral reflux (VUR) is the abnormal backward flow of urine from the bladder into the ureter and kidney during voiding -- from a defective ureteric flap-valve mechanism. VUR is present in 30 to 50% of children who present with febrile UTIs. When infected urine refluxes into the kidney during pyelonephritis, focal cortical scars form (reflux nephropathy) -- cumulatively responsible for 5 to 15% of ESRD in adults. VUR is graded I to V (I -- reflux into the ureter only; V -- severe dilation with loss of calyceal architecture). Grades I to III often resolve spontaneously as the child grows.

Diagnosis: VCUG (voiding cystourethrogram -- the definitive test), DMSA scan (identifies existing cortical scars and differential function). Treatment: continuous antibiotic prophylaxis (trimethoprim) while awaiting spontaneous resolution for low-grade VUR, Deflux endoscopic injection (80 to 90% success for Grade II to III), ureteric reimplantation for Grade IV to V VUR or failed Deflux. At KIMS, siblings of VUR-positive children have a 25 to 33% risk -- sibling screening with renal ultrasound is recommended for all siblings below age 3.

Wilms tumour (nephroblastoma) is the most common renal malignancy in children -- occurring predominantly between ages 3 and 5. It arises from embryonic kidney cells that failed to differentiate normally. Most Wilms tumours are unilateral and sporadic -- approximately 10 to 15% are bilateral. Syndromic associations include WAGR syndrome (Wilms, Aniridia, Genitourinary anomalies, intellectual disability Range -- from WT1 deletion), Beckwith-Wiedemann syndrome, and Denys-Drash syndrome (WT1 point mutation). Presenting features: abdominal mass (detected by a parent or during routine examination -- often large), haematuria, abdominal pain, and hypertension.

CT staging is performed before surgery. Treatment: in most protocols -- initial nephrectomy (or pre-operative chemotherapy for large or bilateral tumours) followed by adjuvant chemotherapy (vincristine + actinomycin D for standard-risk; adding doxorubicin and/or radiotherapy for higher-risk stages). Overall survival above 90% for localised disease with current protocols -- one of the great success stories of paediatric oncology. At KIMS, Wilms tumour is managed jointly by the paediatric urology, paediatric oncology, and nephrology teams. Bilateral Wilms: nephron-sparing surgery to preserve bilateral kidney function.